A photoredox cyanomethylation, optimized in one instrument

EvoluChem™ in the Literature

How GSK Discovered a New Reaction with the Lucent360™ A team at GSK just published a new metallaphotoredox cyanomethylation in Chemistry  A European Journal that produces α-aryl nitriles without toxic cyanide reagents. The serendipitous observation came from a screening run. The optimization, scope, and scale-up to a Senexin drug intermediate were all done on the Lucent360™. Gemma Cook and coworkers reported: "Expedient Discovery of a Metallaphotoredox Cyanomethylation for Synthesizing α-Aryl Nitriles" The paper is a clean illustration of the workflow the Lucent360™ was designed for: HTE-driven optimization, parallel substrate scope, and scale-up. All in one instrument.

Why the Lucent360™ for this kind of work? When a reaction depends on tightly controlled wavelength, intensity, and temperature — and you need to vary all three across a scope — most photoreactors force compromises. The Lucent360™ was built specifically to remove them: Up to 48 samples per run across 5 independently controlled light modules Wavelength flexibility from 254 nm to 808 nm via interchangeable LED modules Temperature control 0 °C to 80 °C via thermostatic bath Light intensity screening with reproducible, programmable presets Batch and flow in the same instrument — 0.3 mL screening up to 700 mL batch, plus 20 mL and 50 mL flow cells In the GSK study, the team used the 24×4 mL holder at 450 nm, held at 40 °C — running a full medicinally relevant substrate scope in parallel — then took the same chemistry to a 48 mmol jacketed batch run for the Senexin intermediate.

 

 

Photoreactor, Lucent360 

더 자세한 정보는 켐코코리아로 문의하세요~!

켐코코리아 주식회사

Tel. 043-215-2012

e-mail. ck@chemcokorea.com

Web. http://www.chemcokorea.com/

Blog. http://blog.chemcokorea.com/